1,070 results
6-K
EX-99.1
SNY
Sanofi
31 Oct 19
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
6:48am
(CVRs) Litigation
PARIS – October 31, 2019: - Sanofi announced today that it has entered into an agreement to settle (the “Settlement Agreement … as discussed below, a total of $315,000,000 U.S.D. (the “Settlement Payment” or “Litigation Proceeds”);
Any and all claims or causes of action
6-K
EX-99.4
SNY
Sanofi
20 Jun 23
Current report (foreign)
10:18am
by Boehringer Ingelheim (“BI”) against Sanofi for indemnification of potential liabilities related to the ongoing Zantac litigation in the U.S. ; decision … of underlying U.S. Zantac litigation as confirmed by developments over the last 6 months
Paris, June 20, 2023. Sanofi announces that in an International
6-K
EX-99.1
SNY
Sanofi
15 Aug 06
Motion Filed for Preliminary Injunction In Plavix® Patent Infringement Case
12:00am
District of New York, where the companies’ ongoing patent litigation against Apotex is pending. The Court has scheduled a hearing on the motion on August … product infringes their intellectual property rights, which are currently the subject of the pending patent litigation. The companies intend to continue
6-K
EX-99.1
SNY
Sanofi
1 Sep 06
Current report (foreign)
12:00am
a bond in the amount of $400 million to provide security to Apotex should the Court conclude at the end of the patent litigation
that the injunction … to believe that the Apotex generic product infringes their intellectual property rights, which are currently the subject of the pending patent litigation
6-K
EX-99.2
SNY
Sanofi
14 Sep 05
Current report (foreign)
12:00am
Paris, September 13, 2005
SETTING OF A TRIAL DATE IN THE UNITED STATES
PLAVIX® LITIGATION
Today sanofi-aventis announced that the U.S. District … Court for the Southern District of New York has set a trial date for the Plavix® patent litigation against Apotex Inc. and Apotex Corp. pending before
6-K
EX-99.2
yvidkisynv
1 Mar 06
Apidra®– A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
12:00am
6-K
EX-99.4
c842ktsjbfu6idj
19 Mar 19
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
10:15am
6-K
EX-99.4
x9h9fxo535xejj7ue9
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
4k9ntb65wsgoa12el5
31 Jul 06
Current report (foreign)
12:00am
6-K
EX-99.4
46vunf155s0 b5v5e
24 Jun 20
R&D strategy driving pipeline momentum, productivity and innovation
3:08pm
6-K
EX-99.1
6v5xm8
7 Apr 20
Current report (foreign)
1:49pm
6-K
EX-99.1
bk92k6
27 Jul 06
Update on Plavix® Litigation Settlement
12:00am
6-K
EX-99.1
pyhpt3lghstgy
29 Apr 10
Sanofi-aventis Announces Court Decision
12:00am
6-K
EX-99.2
7rf92x9ru0i2dgk3
3 May 18
Current report (foreign)
9:23am
6-K
EX-99.5
ar09tmvlqxg
30 Jun 21
Sanofi launches dedicated vaccines mRNA Center of Excellence
5:17pm
6-K
EX-99.2
vj2h001qu1v 8oya6y
22 May 18
New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improvedmoderate-to-severe asthma
9:29am
6-K
EX-99.1
ca8ijgk ptn
8 Aug 06
Update Regarding Plavix® Patent Infrigement Case
12:00am
6-K
r3v qnf0qduu6
21 Apr 10
Current report (foreign)
12:00am
6-K
EX-99.3
f6dxg0b0zljoyv
22 Oct 18
Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
8:58am
6-K
EX-99.1
1j8t8wz
2 Aug 07
Free Translation of the French Language Original
12:00am